Switzerland· 69562001
Adzynma 500 I.E., Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
A apadamtase alfa und cinaxadamtase alfa product containing radamts13, registered in Switzerland by Takeda Pharma AG and dispensed under Swissmedic category B. The same ATC class is registered in 10 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Apadamtase alfa und cinaxadamtase alfa is registered in 10 of 19 countries.
Countries holding a registration under ATC B01AD13 (apadamtase alfa und cinaxadamtase alfa), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Apadamtase alfa und cinaxadamtase alfa · ATC B01AD13
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- rADAMTS13
- Manufacturer
- Takeda Pharma AG
- Country
- Switzerland (CH)
- ATC code
- B01AD13
- ATC class
- Apadamtase alfa und Cinaxadamtase alfa
- Defined daily dose
- 200 E, P
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under B01AD13
Apadamtase alfa und cinaxadamtase alfa, as other registers publish it.
- PolandAdzynmaTakeda Manufacturing Austria AG
- IcelandAdzynmaTakeda Manufacturing Austria AG
- NorwayAdzynmaTakeda Manufacturing Austria AG
- IcelandAdzynmaTakeda Manufacturing Austria AG
- NorwayAdzynmaTakeda Manufacturing Austria AG
- PolandAdzynmaTakeda Manufacturing Austria AG
- DenmarkADZYNMATakeda Manufacturing Austria AG
- FinlandADZYNMATakeda Manufacturing Austria AG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f3d65a70-9a1c-4999-95a5-3b2ba25e0238 GET /v1/drugs/f3d65a70-9a1c-4999-95a5-3b2ba25e0238?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about apadamtase alfa und cinaxadamtase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.